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Chronic inflammation with mucous metaplasia and airway remodeling are hallmarks of
allergic asthma, and these outcomes have been associated with enhanced expression and
activation of EGFR signaling. Here, we demonstrate enhanced expression of EGFR ligands
such as amphiregulin as well as constitutive EGFR activation in cultured nasal epithelial
cells from asthmatic subjects compared with nonasthmatic controls and in lung tissues of
mice during house dust mite–induced (HDM-induced) allergic inflammation. EGFR
activation was associated with cysteine oxidation within EGFR and the nonreceptor tyrosine
kinase Src, and both amphiregulin production and oxidative EGFR activation were
diminished by pharmacologic or genetic inhibition of the epithelial NADPH oxidase dual
oxidase 1 (DUOX1). DUOX1 deficiency also attenuated several EGFR-dependent features
of HDM-induced allergic airway inflammation, including neutrophilic inflammation, type 2
cytokine production (IL-33, IL-13), mucous metaplasia, subepithelial fibrosis, and central
airway resistance. Moreover, targeted inhibition of airway DUOX1 in mice with previously
established HDM-induced allergic inflammation, by intratracheal administration of DUOX1-
targeted siRNA or pharmacological NADPH oxidase inhibitors, reversed most of these
outcomes. Our findings indicate an important function for DUOX1 in allergic inflammation
related to persistent EGFR activation and suggest that DUOX1 targeting may represent an
attractive strategy in asthma management.
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Introduction
Allergic airway diseases are rapidly increasing worldwide and form a significant health burden. While 
many forms of  asthma are successfully managed with current treatments with corticosteroids and/or bron-
chodilators, many asthmatics still suffer from poor management due to steroid resistance or life-threatening 
exacerbations (1, 2). Asthma is commonly viewed as a disease dominated by enhanced adaptive immune 
responses leading to eosinophilic inflammation, but recent evidence indicates that innate immune respons-
es originating from the respiratory epithelium contribute importantly to enhanced inflammation as well as 
mucous metaplasia and airway remodeling, which are important hallmarks of  allergic asthma (3, 4). More-
over, genetic or epigenetic alterations contribute to an altered respiratory epithelium, which is hyperreactive 
to allergen challenges and thereby mediates exaggerated responses to allergens during exacerbations (3, 5).
One well-recognized feature of  epithelial alterations in the asthmatic airway is the increased expression 
of  the EGFR and several of  its ligands, leading to increased and corticosteroid-insensitive EGFR activa-
tion (6–10). Epithelial EGFR activation contributes to several important features of  asthma, including the 
activation of  a chronic wound response within the airways characterized by airway remodeling, mucous 
metaplasia, and neutrophilic inflammation (11–13). Moreover, our recent findings indicate that epitheli-
al EGFR activation also mediates allergen-induced epithelial secretion of  the alarmin IL-33 and subse-
quent activation of  type 2 inflammatory responses (14). Accordingly, several studies in animal models have 
demonstrated that inhibition of  epithelial EGFR can prevent or inhibit many of  these cardinal features; 
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HDM-induced allergic inflammation, by intratracheal administration of DUOX1-targeted siRNA or 
pharmacological NADPH oxidase inhibitors, reversed most of these outcomes. Our findings indicate 
an important function for DUOX1 in allergic inflammation related to persistent EGFR activation and 
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in particular, it affects neutrophilic inflammation, mucous metaplasia, subepithelial fibrosis, and airway 
resistance (15–17). However, these findings have not been translated into clinical use of  available selective 
EGFR tyrosine kinase inhibitors in treatment of  asthma, as EGFR tyrosine kinase inhibitors are associated 
with adverse effects, such as enhanced skin rash and inflammation (18). In addition, while EGFR tyrosine 
kinase inhibitors are used successfully in the treatment of  lung cancers, they commonly induce acquired 
resistance due to the promotion of  secondary EGFR mutations (19), thus significantly limiting their use 
in less life-threatening chronic diseases. A recent clinical trial using the EGFR inhibitor BIBW 2948 in 
patients with COPD indicated efficacy with respect to inhibiting EGFR activation and a tendency toward 
reducing mucous metaplasia but was terminated due to adverse effects such as reversible liver enzyme ele-
vation and decreased forced expiratory volume in 1 second (FEV1) in some patients (20). Therefore, alter-
native strategies to more selectively prevent or suppress airway EGFR activation in the context of  chronic 
or severe asthma, while avoiding these adverse outcomes, would be desirable.
In spite of  the strong evidence implicating chronic epithelial EGFR expression and activation in the 
pathophysiology of  asthma, the proximal mechanisms leading to such persistent EGFR activation are 
poorly understood. Our recent studies as well as those by others have revealed an oxidative mechanism of  
airway EGFR activation in response to injury or to challenge with common airborne allergens that involves 
initial activation of  the epithelial NADPH oxidase dual oxidase 1 (DUOX1) (14, 21, 22). DUOX1-medi-
ated EGFR activation involves a cascade of  events, including activation of  the redox-sensitive nonreceptor 
tyrosine kinase Src and production of  soluble EGFR ligands (23, 24). In addition, DUOX1 also contrib-
utes to enhanced EGFR tyrosine kinase activity by promoting cysteine oxidation within EGFR itself  (14, 
25). The relevance of  these findings for asthma is supported by recent findings that DUOX1 expression is 
enhanced in nasal epithelial cells (NECs) from subjects with allergic asthma and rhinosinusitis (14, 26). 
Based on these considerations, we hypothesized that enhanced epithelial DUOX1 activation may con-
tribute to persistent EGFR activation, activation of  type 2 immune responses, and related pathological 
events during allergic asthma, such as mucous metaplasia, airway remodeling, and hyperresponsiveness, 
and that selective targeting of  DUOX1 may attenuate these outcomes. The present studies indeed indicate 
that DUOX1 critically contributes to sustained EGFR activation during allergic asthma through direct 
epithelial oxidative mechanisms and indirect mechanisms involving activation of  type 2 innate lymphoid 
cells (ILC2s) and production of  the EGFR ligand amphiregulin (AREG). Moreover, DUOX1 was found 
to contribute to cardinal features of  allergic inflammation and remodeling in a mouse model of  house dust 
mite–induced (HDM-induced) allergic asthma, and genetic and pharmacological targeting of  DUOX1 was 
able to reverse these outcomes.
Results
EGFR phosphorylation and cysteine oxidation are enhanced in NECs from asthmatic subjects. We recently col-
lected NECs from a cohort of  subjects with allergic asthma and nonasthmatic controls, which indicat-
ed enhanced DUOX1 expression in asthmatic epithelia (14). Secondary analysis of  protein extracts or 
cDNAs from these NECs indicated a consistent presence of  activated (phosphorylated) EGFR as well 
as Src, a critical mediator of  EGFR activation (23), in NECs from asthmatic subjects compared with 
nonasthmatic controls (Figure 1A), in addition to dramatically increased mRNA expression of  several 
EGFR ligands, with 2- to 6-fold increases in EGF and TGFA mRNA and 4- to 90-fold increases in AREG 
in NECs from subjects with asthma (Figure 1B). Moreover, the extent of  EGFR phosphorylation at 
tyrosine 1068 and AREG mRNA expression in NECs from subjects with asthma in both cases inversely 
correlated with reduced lung function, as measured as percentage of  FEV1 (Figure 1C). Because NECs 
from asthmatic subjects contain increased levels of  DUOX1 (14), we postulated that increased EGFR 
and Src activation in asthmatic epithelia was associated with increased cysteine oxidation of  these kinas-
es. To address this, we cultured NECs from healthy and asthmatic subjects to confluence and harvested 
cell lysates after overnight culture in EGF-depleted culture medium in the presence of  DCP-Bio1, a 
dimedone-based derivatizing agent that reacts with protein sulfenic acids (-SOH, the primary cysteine 
oxidation product) to add a biotin tag. Whereas no detectable phosphorylation of  EGFR or Src was 
observed in NECs from nonasthmatic controls in this case, marked increases in EGFR and Src phos-
phorylation were detected in asthmatic NECs (Figure 1D), which most likely coincided with increased 
EGFR ligand expression (Figure 1B). Moreover, these increases in EGFR/Src phosphorylation coin-
cided with marked increases in cysteine oxidation within these proteins, as determined by Western blot 
3insight.jci.org   doi:10.1172/jci.insight.88811
R E S E A R C H  A R T I C L E
analysis of  avidin-purified proteins from DCP-Bio1–derivatized NEC lysates for EGFR or Src (Figure 
1D). These findings indicate the presence of  persistent EGFR activation in asthmatic epithelia, which is 
likely sustained by autocrine or paracrine EGFR ligand production and enhanced oxidative mechanisms 
that promote EGFR activation. To address the role of  DUOX1 in such ligand-induced EGFR activation 
and cysteine oxidation, we used the human bronchial epithelial cell line HBE1 and evaluated tyrosine 
phosphorylation and cysteine oxidation of  EGFR and Src after stimulation with EGF or AREG. In both 
cases, ligand-induced stimulation of  phosphorylation and oxidation of  EGFR and Src were attenuated 
Figure 1. EGFR activation and oxidation are enhanced in nasal epithelial cells from asthmatic subjects. (A) Western blot of phosphorylation status of 
EGFR and Src in primary cultures of NECs from 7 healthy and 7 asthmatic subjects. (B) RT-PCR analysis of EGFR ligands EGF, AREG, and TGF-α (TGFA) in 
NECs from healthy (n = 17) and asthmatic (n = 13) subjects; box, 25th–75th quartiles; whiskers, minimums and maximums. *P < 0.01 by 2-tailed unpaired 
t test. (C) Inverse correlation between percentage of FEV1 and EGFR phosphorylation status (determined by densitometry of pEGFR/EGFR ratio) as well 
as relative AREG mRNA expression in NECs from asthmatic subjects. (D) Western blot analysis of EGFR and Src phosphorylation in association with 
cysteine oxidation in cultured NECs from 7 healthy and 7 asthmatic subjects, determined with phospho-specific antibodies and analysis of avidin-purified 
proteins after DCP-Bio1 derivatization of oxidized cysteines (-SOH). (E and F) Analysis of EGF- or AREG-induced activation and cysteine oxidation in HBE1 
cells transfected with either NS siRNA or DUOX1 siRNA (E) or mTECs from wild-type or Duox1–/– mice (F). Representative blots of at least 2 independent 
experiments are shown.
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after siRNA silencing of  DUOX1 (Figure 1E). Similarly, dose-dependent activation of  EGFR and Src 
in cultured mouse tracheal epithelial cells (mTECs) in response to Areg was attenuated in mTECs from 
Duox1–/– mice compared with WT mice, which was closely associated with corresponding changes in 
cysteine oxidation within these kinases (Figure 1F). Collectively, these findings indicate that persistent 
EGFR activation within epithelia of  asthmatic subjects involves oxidative mechanisms originating from 
DUOX1, which can promote EGFR ligand shedding (23, 27) and enhance EGFR tyrosine kinase activi-
ty by promoting cysteine oxidation with the kinase domain (25).
DUOX1 contributes to oxidative EGFR activation in HDM-induced allergic asthma in mice. To determine 
whether enhanced airway DUOX1 expression and activation contribute to airway EGFR activation and 
protein cysteine oxidation in an experimental model of  allergic asthma, we subjected C57BL6/J mice to 
HDM-induced allergic inflammation (28, 29) (Figure 2A) and evaluated lung tissues for DUOX1 expres-
sion and phosphorylation and cysteine oxidation of  EGFR and Src. As expected (14), we observed sig-
nificantly increased lung tissue levels of  Duox1 mRNA in HDM-treated mice, with only minor chang-
es in Duox2 mRNA (Figure 2B). Accordingly, increased DUOX protein levels were detected within the 
airway epithelia of  HDM-treated wild-type C57BL/6J mice, which was not observed in Duox1–/– mice 
(Figure 2, C and D), confirming that DUOX immunoreactivity originated from DUOX1. To determine 
whether increased DUOX1 expression was associated with increased overall protein cysteine oxidation 
during HDM-induced inflammation, lung tissues were derivatized with DCP-Bio1 and the presence of  
sulfenylated proteins was visualized by streptavidin blotting. Indeed, HDM-treated mice displayed dramat-
ically increased levels of  sulfenylated proteins within lung tissues, which was largely prevented in Duox1–/– 
mice (Figure 2E). Consistent with earlier reports (15) and our observations with NECs, airway EGFR 
phosphorylation was enhanced during HDM-induced allergic inflammation (Figure 2, F and G), as was 
phosphorylation of  Src (Figure 2G), and this was associated with increased cysteine oxidation within these 
kinases (Figure 2G). HDM-induced EGFR phosphorylation was also associated with enhanced lung tissue 
mRNA expression of  the EGFR ligand Areg and elevated production of  AREG in bronchoalveolar lavage 
(BAL) fluids (Figure 2H). Finally, HDM-induced AREG production, as well as EGFR/Src activation and 
oxidation, was dramatically attenuated in Duox1–/– mice compared with wild-type mice (Figure 2, F–H), 
demonstrating the critical contribution of  DUOX1 in sustained airway EGFR activation during allergic 
inflammation. Collectively, these findings indicate that HDM-induced allergic asthma is associated with 
enhanced DUOX1 expression in the airways and DUOX1-mediated persistent activation of  EGFR within 
the airway epithelium.
DUOX1 contributes to HDM-induced neutrophilic inflammation, mucous metaplasia, subepithelial fibrosis, and 
airways hyperresponsiveness. HDM-induced airway inflammation was assessed by enumeration of  inflamma-
tory cells in the BAL (Figure 3A) and by H&E staining of  lung tissue sections (Supplemental Figure 1A; 
supplemental material available online with this article; doi:10.1172/jci.insight.88811DS1), which indicat-
ed marked inflammation in HDM-challenged mice, with dramatic increases in BAL eosinophils and lym-
phocytes as well as modest increases in neutrophils. DUOX1 deficiency had minimal effect on the overall 
inflammatory response and on eosinophil infiltration but dramatically attenuated HDM-induced recruit-
ment of  neutrophils (Figure 3A). Airway epithelial EGFR activation has been linked with neutrophilic 
inflammation in severe human asthma (11) and with HDM-induced neutrophilia in mice (15), suggesting 
that the observed contribution of  DUOX1 to neutrophilic inflammation in the present studies is related 
to its role in epithelial EGFR activation. Another critical feature of  allergic airway inflammation that has 
been strongly associated with airway epithelial EGFR activation is the development of  mucous goblet 
cell metaplasia (12, 13). As expected, HDM-induced allergic inflammation was associated with increased 
presence of  airway mucus, as visualized by PAS staining (Figure 3B), and enhanced lung tissue expression 
of  the mucous metaplasia genes Muc5ac, Clca1, and Postn (Supplemental Figure 1B), and each of  these out-
Figure 2. DUOX1 contributes to oxidative EGFR activation in house dust mite–induced allergic asthma in mice. (A) Experimental design of house dust 
mite–induced (HDM-induced) allergic inflammation. (B) Analysis of DUOX1 and DUOX2 mRNA in lung tissues. (C and D) Analysis of DUOX1 protein expres-
sion in lung tissues using immunofluorescence (C; nuclei counterstained in blue; original magnification ×10) or Western blot analysis (D). (E) Analysis of 
protein cysteine sulfenylation by DCP-Bio1 labeling of lung tissue homogenates and streptavidin blotting. (F and G) Analysis of EGFR activation by IHC 
for phosphorylated EGFR (Y1068) (F) and Western blot analysis of lung tissue homogenates for tyrosine phosphorylation and cysteine oxidation (-S-OH, 
using DCP-Bio1 labeling) within EGFR or Src (G). Scale bars: 100 μm. (H) Quantitation of lung tissue Areg mRNA expression and Areg levels in BAL fluids. 
Qualitative data are representative of 3 separate experiments. Dot plots indicate mean ± SD of 6–10 replicates from 3 independent experiments. *P < 0.05 
compared with corresponding controls, by 2-way ANOVA.
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Figure 3. DUOX1 contributes to house dust mite–induced 
neutrophilic inflammation, mucous metaplasia, subep-
ithelial fibrosis, and airways hyperresponsiveness. (A) 
Quantification of total and differential cell counts in BAL 
fluids. (B) Analysis of mucous metaplasia by histochemical 
analysis of PAS staining and quantification of positive 
staining areas using Metamorph software. (C) Quantifica-
tion of Muc5ac protein in BAL fluids by ELISA. (D and E) 
Evaluation of subepithelial fibrosis by Masson’s trichrome 
staining (D) or α-SMA immunostaining (E), as quantified 
by staining score or percentage of staining around airways. 
Scale bars: 50 μm. (F) Analysis of airways central airway 
resistance (Rn) in response to methacholine challenge. 
Representative histochemical images are shown, and 
dot plots represent mean ± SD of 8–12 replicates from 3 
independent experiments. *P < 0.05 compared with corre-
sponding controls, using 2-way ANOVA.
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comes was significantly attenuated in Duox1–/– mice (Figure 3B and Supplemental Figure 1B). Moreover, 
HDM-induced mucus production was also demonstrated by increased levels of  Muc5ac protein in the 
BAL, which were also significantly attenuated in Duox1–/– mice (Figure 3C).
In addition to promoting mucous metaplasia, epithelial EGFR activation has also been implicated in 
allergen-induced subepithelial fibrotic remodeling (15, 16). In agreement with this, HDM-induced inflam-
mation was associated with significant subepithelial collagen deposition around peripheral airways, as 
detected by Masson’s trichrome staining (Figure 3D) and accumulation of  α-smooth muscle actin (α-SMA) 
(Figure 3E), and induced lung tissue expression of  the collagen genes Col1a1 and Col3a1 (Supplemental 
Figure 1B), and each of  these outcomes was significantly reduced in Duox1–/– mice (Figure 3E and Sup-
plemental Figure 1B). Finally, HDM treatment also resulted in enhanced airway hyperresponsiveness to 
methacholine, as shown by increased resistance of  the conducting airways (Rn), which was also significant-
ly attenuated in Duox1–/– mice (Figure 3F and Supplemental Figure 1C). Collectively, these findings indi-
cate that epithelial DUOX1 mediates a number of  critical features of  allergic airway inflammation, most 
notably neutrophilia, mucous metaplasia, subepithelial fibrosis, and airways hyperresponsiveness. Since 
each of  these outcomes have in previous studies been linked with enhanced epithelial activation of  EGFR 
(12, 15, 16), our findings are consistent with the hypothesis that DUOX1 contributes to these phenotypes 
largely by promoting persistent EGFR activation within the airway epithelium.
DUOX1 participates in HDM-induced neutrophil chemokine and type 2 cytokine production from epithelia and 
ILC2s. DUOX1-dependent EGFR activation can promote airway epithelial production of  the neutrophil 
chemokine IL-8 (27, 30). Analysis of  BAL fluids from HDM-challenged wild-type mice indicated marked 
and DUOX1-dependent increases of  the mouse functional IL-8 homolog CXCL1, consistent with the 
observed DUOX1-dependent neutrophilia in this model (Figure 4A). In addition, DUOX1 was also found 
to be critical for HDM-induced increases in lung tissue mRNA levels of  Cxcl1 (Supplemental Figure 2A).
We recently highlighted a critical role of  DUOX1 in epithelial IL-33 secretion and induction of  type 2 
cytokines in response to acute challenge to allergens such as HDM (14). In agreement with these findings, 
BAL fluids from HDM-challenged mice demonstrated increased levels of  IL-33, as well as the type 2 cyto-
kines IL-5 and IL-13 (Figure 4B), which were associated with corresponding increases in lung tissue mRNA 
levels (Supplemental Figure 2B), and each of  these responses was dramatically suppressed in HDM-treat-
ed Duox1–/– mice. Serum levels of  HDM-specific IgG1 and IgE indicated were highly similar between 
HDM-challenged wild-type and Duox1–/– mice (Supplemental Figure 2C), suggesting that DUOX1-depen-
dent type 2 responses are largely independent of  adaptive immune responses and are most likely related to 
expansion and activation of  ILC2s, which could serve as the primary source of  IL-5, IL-3, and the EGFR 
ligand AREG in response to epithelial-derived cytokines, such as IL-33, within the lung (31–33). To address 
this, we generated single-cell suspensions of  lung tissues from both control and HDM-challenged mice for 
in vitro restimulation with IL-33, which revealed dramatically enhanced production of  IL-5, IL-13, and 
Areg by lung cell suspensions from HDM-challenged wild-type mice but not from Duox1–/– mice (Figure 
4C). These findings would suggest that HDM-induced recruitment of  lung ILC2s is attenuated in Duox1–/– 
mice, but analysis of  lung tissue ILC2 populations using flow cytometry analysis of  lineage-negative, 
CD90+ Ly6A (Sca-1)+ cell populations (Supplemental Figure 3) did not demonstrate reduced lung ILC2 
populations in HDM-exposed Duox1–/– mice compared with HDM-challenged wild-type mice (Figure 4, 
D and E); in fact, increased ILC2 recruitment in Duox1–/– mice was indicated. Therefore, DUOX1 may be 
involved more directly in ILC2-dependent production of  type 2 cytokines and AREG. To test this, lung 
ILC2 populations were expanded in wild-type and Duox1–/– mice by repeated intranasal IL-33 exposure 
(32) and collected by flow sorting for analysis of  DUOX1 protein by Western blot as well as for analysis 
of Il5, Il13, and Areg mRNA expression as specific markers of  ILC2 development. IL-33–mediated ILC2 
recruitment was comparable between WT and Duox1–/– mice, but ILC2s from IL-33–challenged Duox1–/– 
mice expressed markedly reduced mRNA levels of  Il5, Il13, and Areg compared with ILC2s from wild-type 
mice (Figure 4F). Moreover, lung ILC2s were found to express DUOX1 protein (Figure 4G), suggesting 
that the observed reduction of  HDM-induced type 2 responses in Duox1–/– mice is at least partially due to 
attenuated DUOX1-mediated activation of  ILC2s. Type 2 cytokines and AREG can also be produced by 
airway epithelial cells (34, 35), and in vitro stimulation of  isolated mTECs with IL-33 produced significant 
amounts of  IL-13 and AREG indeed; these responses were markedly attenuated in mTECs from Duox1–/– 
mice (Supplemental Figure 2D). In aggregate, these findings establish that DUOX1 is pivotal for epithelial 
production of  CXCL1 and IL-33 but also mediates subsequent activation of  type 2 cytokines, such as IL-13 
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and AREG, by both epithelial cells and ILC2s (Figure 4G). Collectively, these events contribute to the 
observed persistent epithelial activation of  EGFR, and enhanced neutrophilia, mucous metaplasia, and 
fibrotic remodeling, during HDM-induced allergic inflammation.
DUOX1 targeting during ongoing allergic inflammation attenuates EGFR activation, mucous metaplasia, 
and fibrotic remodeling. While these data establish that DUOX1 contributes markedly to development 
of  several clinically relevant features of  allergic asthma, it does not necessarily imply that targeting of  
DUOX1 can reverse or attenuate these outcomes in ongoing allergic airway disease. To test this, we 
administered Duox1-targeted siRNA into the airways of  mice after establishing HDM-induced aller-
gic inflammation (Figure 5A) to evaluate the ability of  DUOX1 suppression to reverse symptoms of  
ongoing allergic asthma phenotypes or asthma exacerbations. siRNA-dependent DUOX1 targeting 
was efficacious and significantly reduced Duox1 expression in lung tissues (Supplemental Figure 4A) 
and markedly attenuated HDM-induced activation and oxidation of  EGFR and Src within the lung 
(Figure 5B). Moreover, siRNA targeting of  Duox1 was capable of  reversing several critical phenotypes 
of  HDM-induced allergic inflammation, such as neutrophil infiltration (Figure 5C), type 2 cytokine 
responses (Figure 5D and Supplemental Figure 4B), indices of  mucous metaplasia (Figure 5, E and F, 
and Supplemental Figure 4C), and fibrotic remodeling (Figure 5G and Supplemental Figure 4, C and 
D). Finally, Duox1 silencing tended to attenuate HDM-induced central airway resistance in response 
to methacholine challenge, although differences were not statistically significant (Supplemental Figure 
4D). Collectively, these findings indicate that DUOX1 targeting in a model of  previously established 
asthma is capable of  reversing several clinical relevant asthma features.
To date, no specific pharmacological inhibitors of  DUOX1 are available. While several drug screening 
and development efforts have identified inhibitors with some specificity against several NADPH oxidase 
isoforms, none of  these have been tested for efficacy against DUOX1 (36). We performed preliminary 
analysis of  several putative NADPH oxidase inhibitors to evaluate their ability to inhibit DUOX1 activa-
tion in HBE1 cells, which was assessed by analysis of  ATP-stimulated extracellular H2O2 production and 
IL-33 secretion (14, 23). Both ATP-stimulated H2O2 production and IL-33 secretion were inhibited in a 
dose-dependent fashion by the nonselective NADPH oxidase inhibitor diphenylene iodonium (DPI) as 
well as ML171, a phenothiazine compound that was recently identified in a high-throughput drug screen 
as a relatively selective NOX1-selective inhibitor but was not tested against DUOX1 (37), with IC50 values 
in the order of  0.1–1 μM (Supplemental Figure 5, A and B). By comparison, two other NOX inhibitors, 
apocynin and VAS2870 (36), were relatively ineffective at concentrations up to 10 μM (Supplemental Fig-
ure 5A). We evaluated the ability of  DPI or ML171 to attenuate intrinsic EGFR activation and oxidation 
in cultured NECs from asthmatic subjects and found that both inhibitors consistently suppressed basal 
phosphorylation and oxidation of  both EGFR and Src in NECs from at least 3 separate asthmatic subjects 
(Figure 6A). We extended these findings by intranasal administration of  either inhibitor into the airways 
of  mice with ongoing HDM-induced allergic inflammation (Figure 6B), which similarly suppressed oxi-
dation and activation of  both EGFR and Src (Figure 6C). Administration of  DPI and ML171 did not 
significantly alter HDM-induced inflammatory BAL cell counts, although they tended to suppress inflam-
mation (Supplemental Figure 5C) and to attenuate methacholine-induced central airway resistance in 
HDM-treated mice (Supplemental Figure 5D). Moreover, both inhibitors significantly suppressed produc-
tion of  type 2 cytokines (Figure 6D and Supplemental Figure 5E) as well as indices of  mucous metaplasia 
and fibrotic remodeling (Figure 6E and Supplemental Figure 5F). The close association of  these outcomes 
with DUOX1 activation suggests that these inhibitors acted largely by inhibiting DUOX1, although inhib-
itory actions on other NOX isozymes may have contributed as well. Collectively, these results demonstrate 
that pharmacological targeting of  DUOX1 in the airways is potentially clinically useful as a therapeutic 
approach to minimize persistent airway EGFR activation and consequent neutrophilia, mucous metapla-
sia, and fibrotic remodeling, which are especially important in severe asthma.
Figure 4. DUOX1 mediates type 2 cytokine responses and ILC2 activation during house dust mite–induced inflammation. (A and B) Analysis of BAL cytokine 
levels of CXCL1 (KC) (A) and of type 2 cytokines, IL-33, IL-5, and IL-13 (B). (C) Analysis of IL-33–induced (10 ng/ml) production of ILC2-specific cytokines (IL-5, 
IL-13) and AREG from lung single-cell suspensions of PBS- or HDM-treated mice. (D and E) Flow cytometry analysis of ILC2 populations in lung tissues. (F) 
RT-PCR analysis of flow-sorted lung ILC2 populations from IL-33–triggered mice for type 2 cytokines, Areg, and Duox1. (G) Representative western blot analy-
sis of Duox1 protein and β-actin in sorted ILC2 cells (mILC2) and primary mTECs. (H) Schematic representation of proposed interactions among DUOX1, EGFR, 
IL-33, and IL-13 within the airway. Black arrows reflect enzyme activation or stimulation of cytokine secretion, and red arrows indicate effects on mRNA expres-
sion. Dot plots represent mean ± SD of 8–12 replicates from 2–3 separate experiments. *P < 0.05 compared with corresponding controls by 2-way ANOVA.
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Discussion
The most significant findings of  the studies presented here are that the epithelial NADPH oxidase DUOX1 
regulates several clinically important features of  allergic asthma and that DUOX1 targeting is capable 
of  reversing features of  ongoing allergic inflammation. While DUOX1-dependent redox signaling may 
potentially affect many diverse pathways (e.g., refs. 38, 39), the contribution of  DUOX1 to allergic inflam-
mation was found to be closely related to its role in persistent oxidant-dependent epithelial activation of  
EGFR and consequent production of  neutrophil chemokines and type 2 cytokines such as IL-13, which 
results in promotion of  neutrophilic inflammation, mucous metaplasia, subepithelial fibrotic remodeling, 
and central airway resistance. The importance of  airway EGFR activation to these various features of  
allergic asthma is well recognized (11, 15, 17), but existing EGFR tyrosine kinase inhibitors have not been 
evaluated for clinical application in chronic lung diseases such as asthma, because of  the broad role of  
EGFR in various organ systems and reported adverse effects that are tolerable in severe or fatal lung dis-
eases, such as lung cancer, but not in lung diseases that are not immediately life-threatening (12, 18–20). 
The fact that DUOX1 expression is largely restricted to epithelial lineages (39), including the lung, renders 
it a more appealing therapeutic target, with the potential of  avoiding unwanted side effects associated with 
EGFR inhibitors administered systemically. Our findings indicate that inhibition of  DUOX1 may be capa-
ble of  disrupting the persistent cycle of  EGFR activation and activation of  type 2 cytokines such as IL-13, 
which sustain mucous cell metaplasia and fibrotic remodeling within the asthmatic airway. Moreover, we 
present evidence that DUOX1 targeting in mice with previously established allergic airway inflammation 
and remodeling can attenuate these outcomes. To our knowledge, our findings are the first to establish the 
causal participation of  DUOX1 in any disease pathology. Related findings were recently observed in mice 
deficient in Duoxa genes, resulting in overall functional DUOX1/2 deficiency, which similarly showed lack 
of  neutrophilia, type 2 cytokine responses, and mucous cell metaplasia in an alternative model of  allergic 
asthma (40); however, these studies did not address the specific roles of  either DUOX1 or DUOX2, which 
have distinct and nonredundant functions in various organ systems (38, 39). Our present findings therefore 
provide a strong incentive for the development of  DUOX1-targeted pharmacological approaches for clini-
cal use, as DUOX1 has so far been relatively ignored in screening efforts for NOX-selective inhibitors (36).
Goblet cell hyperplasia and mucus hypersecretion are important features in the conducting airways 
during allergic asthma, and extensive mucus plugging is associated with fatal asthma episodes (41). Ani-
mal models of  allergic asthma support the critical role of  the mucin gene Muc5ac in the development of  
mucus obstruction and airway hyperreactivity (42). The process of  mucus hypersecretion during allergic 
asthma involves a complex multistep process, including mucin gene induction, mucus packaging in storage 
granules, mucus secretion, and changes in extracellular mucus viscosity. Both EGFR and IL-13 are known 
to contribute to mucous cell metaplasia by promoting mucin gene induction (e.g., MUC5AC, CLCA1) 
through independent and still incompletely understood mechanisms (43, 44). The present findings indi-
cating a role for DUOX1 in induction of  various genes associated with mucous cell metaplasia (Muc5ac, 
Clca1, Postn) are consistent with previous observations (22) and are in keeping with the presence of  DUOX1 
in the central airways and the observed enhanced central airway resistance in response to methacholine. 
Enhanced IL-13 production during allergic asthma has also been strongly associated with airway remodel-
ing and subepithelial fibrosis by incompletely understood mechanisms that include alternative macrophage 
activation, induction of  collagen deposition, and myofibroblast proliferation (41). The observed contribu-
tion of  DUOX1 to subepithelial fibrosis is most likely a result of  its importance in IL-13 production by both 
epithelial cells and ILC2s. Recent development of  various antibody-based targeting strategies against IL-13 
and its receptor have been met with mixed success (41), and because of  the excessive costs of  such anti-
body-based approaches, pharmacologic targeting of  DUOX1 with small-molecule inhibitors to minimize 
IL-13 production might represent an attractive and potentially equally effective alternative.
Figure 5. DUOX1 targeting reverses house dust mite–induced EGFR activation, type 2 immune responses, and airway remodeling. (A) C57BL/6J mice 
were subjected to house dust mite–induced (HDM-induced) inflammation and were subsequently targeted with DUOX1 siRNA. (B) Western blot analysis 
of EGFR and Src activation and cysteine oxidation, as in Figure 2. (C) Quantitation of BAL total cell counts and neutrophils. (D) ELISA analysis of BAL type 
2 cytokines and AREG. (E and F) Evaluation of mucous metaplasia by PAS staining (E) and Muc5ac ELISA of BAL fluids (F). (G) Evaluation and quantifica-
tion of α-smooth muscle actin (SMA) immunoreactivity. Scale bars: 50 μm. White and black dots represent analysis at day 22 (3 days after final HDM chal-
lenge), and red dots reflect analysis at day 25 (6 days after final HDM and 3 days after siRNA instillation). Dot plots represent mean ± SD of 6–10 replicates 
from 2 separate experiments. *P < 0.05 compared with corresponding controls, by 2-way ANOVA.
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Our findings highlight the complex and reciprocal interactions of  DUOX1 with both EGFR activation 
and type 2 cytokine signaling (IL-33, IL-13), both well-known features of  allergic asthma, and indicate 
that DUOX1 may contribute to sustained activation of  these pathways through several positive feedback 
loops (Figure 4H). First, DUOX1 critically contributes to EGFR activation in response to external damag-
ing stimuli, including allergens, by promoting epithelial IL-33 secretion and subsequent activation type 2 
cytokine responses (IL-5, IL-13) in ILC2s, for example, as well as other lung cell types (14). In turn, IL-13 
is capable of  enhancing epithelial EGFR activation and inducing epithelial expression of  DUOX1 (45) as 
well as IL-33 and its receptor (IL33R, also known as ST2) (46), thus generating positive feedback loops that 
result in amplified and prolonged epithelial responses to allergen challenge. An additional consequence of  
IL-33–mediated ILC2 recruitment and activation is the production of  AREG, which forms an essential 
component of  EGFR-mediated epithelial repair responses in the context of  parasite/helminth infection 
(47) but may also contribute to sustained EGFR activation in chronic asthma. Moreover, DUOX1 contrib-
utes to EGFR activation not only by promoting EGFR ligand activation, as previously reported (23, 27), 
but also by promoting ligand-induced activation of  EGFR phosphorylation by direct cysteine oxidation 
within EGFR. Although chronic epithelial alterations during allergic asthma are commonly attributed to 
epigenetic changes, potentially involving important asthma-relevant cytokines such as IL-13 (8, 48, 49), our 
Figure 6. Pharmacological NOX inhibition suppresses EGFR activation and type 2 immune responses in asthmatic airways. (A) Western blot analysis 
of activation and cysteine oxidation of EGFR and Src in NECs from 2 healthy (C1, C2) and 3 asthmatic subjects (A1–A3), after 30 minutes of preincubation 
with the NOX inhibitors DPI (1 μM) or ML171 (5 μM). (B) C57BL/6J mice were subjected to house dust mite–induced (HDM-induced) allergic inflammation 
and subsequently administered DPI or ML171 and harvested at day 25 (6 days after final HDM challenge). (C) Western blot analysis of activation and cys-
teine oxidation of EGFR and Src in lung tissues collected at day 25. (D) ELISA analysis of type 2 cytokines in BAL fluids, harvested at day 25. (E) Evaluation 
of mucous metaplasia markers in lung tissues by RT-PCR and Muc5ac ELISA of BAL fluids, harvested at day 25. Representative Western blots are shown. 
Dot plots represent mean ± SD of 6–10 replicates from 2 separate experiments. *P < 0.05 compared with corresponding controls, by 2-way ANOVA.
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results indicate that such alterations are also mediated by redox-dependent mechanisms due to enhanced 
expression and activation of  DUOX1 and can be attenuated by inhibition of  DUOX1.
Although several EGFR ligands are known to be activated in the airways of  asthmatic subjects, the 
relative contribution of  these ligands in disease pathology is unclear. In this light, it is intriguing that AREG 
differs from other EGFR ligands such as EGF in that it has lower receptor affinity and thus results in 
sustained EGFR activation, in contrast to rapid EGFR internalization and degradation by other EGFR 
ligands, with distinct cellular consequences (47). Elevated AREG levels are detected in asthmatic airways, 
especially after exacerbations (9), and AREG appears to be the most strongly upregulated EGFR ligand in 
NECs from asthmatics (according to the present studies) and is also a major product of  activated ILC2s. 
These observations suggest that AREG is primarily responsible for the observed sustained EGFR activation 
in asthmatic airways. Moreover, AREG may also contribute to mucous cell metaplasia in some conditions, 
although its contribution to mucous cell metaplasia in the context of  allergic asthma is less clear (50). 
Although the EGF ligands responsible for the various asthma phenotypes need to be further unraveled, 
DUOX1 is clearly involved in EGFR activation irrespective of  the activating ligand.
The interactions among DUOX1, EGFR, and IL-33/IL-13 responses are even further complicated by 
our unanticipated finding that DUOX1 also participates in IL-33–dependent activation of  type 2 responses 
in epithelial cells as well as ILC2s. The mechanism by which DUOX1 promotes IL-33–dependent signal-
ing will need to be addressed in future studies but potentially involves amplification of  IL33R-dependent 
JAK/STAT signaling by oxidative inhibition of  protein tyrosine phosphatases, analogous to other cytokine 
signaling pathways (51). Moreover, the observed expression of  DUOX1 in ILC2s, combined with recent 
reports indicating the presence of  DUOX1 in T cells (51) and macrophages (52), implies that the involve-
ment of  DUOX1 in lung biology extends beyond its well-studied role(s) in epithelial host responses (53) 
and likely also includes regulatory functions in other cell lineages. Future studies, using transgenic models 
of  targeted DUOX1 deletion in these various cell lineages, for example, will be required to unravel the spe-
cific contribution of  DUOX1-dependent signaling in these specific cell types.
The critical function of  DUOX1 in induction of  type 2 cytokine responses (including IL-5) during 
HDM-induced inflammation appears to be at odds with the relative lack of  impact of  DUOX1 on HDM-in-
duced eosinophilia. One potential explanation for this may be the fact that ILC2 can produce IL-5 constitu-
tively to control eosinophil homeostasis (54), whereas IL-13 production requires ILC2 stimulation by IL-33 
and/or IL-25 (55). Indeed, observations of  enhanced accumulation of  ILC2 populations during HDM-in-
duced inflammation in DUOX1-deficient mice would suggest that constitutive IL-5 production by these 
ILC2s may have been sufficient to promote eosinophil recruitment, even though IL-33–mediated induction 
of  IL-5 is impaired in these cells.
Our studies are primarily based on the premise that DUOX1 activation generates H2O2 as its primary 
product and that H2O2 affects protein function by cysteine oxidation to sulfenic acids and related oxidative 
modifications such as S-glutathionylation (38, 39). Although the present studies focused primarily on sulfe-
nylation as a mechanism of  oxidative EGFR activation, based on recent findings (25, 56), we cannot rule 
out the potential contribution of  protein glutathionylation within EGFR or in other bystander proteins in 
mediating DUOX1-related allergic inflammation (e.g., ref. 57, 58). Likewise, it is plausible that H2O2 gives 
rise to production of  other (secondary) reactive intermediates that would expand the range of  potential oxi-
dative posttranslational modifications that affect protein function. Although such additional mechanisms 
cannot be ruled out, our present findings indicate that oxidant-mediated activation of  EGFR signaling rep-
resents a major mechanism by which DUOX1 contributes to allergic airway inflammation and remodeling.
In summary, the findings presented here highlight a critical function of  airway DUOX1 in promot-
ing epithelial EGFR activation and subsequent cytokine responses and airway remodeling during allergic 
asthma and furthermore demonstrate that therapeutic targeting of  DUOX1 has the potential of  reversing 
these outcomes in cases of  severe asthma and potentially in cases of  exacerbations. Although the pharma-
cological NOX inhibitors used in this study may not be suitable for clinical development (36), they strongly 
support the proof  of  concept that selective targeting of  DUOX1 may have excellent therapeutic potential.
Methods
Study design. This study was designed to address the importance of  increased DUOX1 expression in the air-
ways of  subjects with allergic asthma and its role in mediating EGFR activation as a major feature of  epi-
thelial alterations that drive type 2 inflammation and airway remodeling (14). Primary human NECs were 
1 4insight.jci.org   doi:10.1172/jci.insight.88811
R E S E A R C H  A R T I C L E
collected from a cohort of  17 healthy volunteers and 16 subjects with allergic rhinitis and asthma (14). Ato-
py was confirmed by positive skin tests and elevated serum IgE (>100 IU/ml), and asthma was confirmed 
by positive response to bronchodilator (≥200 cc and 12% improvement in FEV1 and/or FVC) or a positive 
methacholine challenge test (PC20 < 8 mg/ml). Healthy volunteers had no history of  rhinitis or asthma, 
negative skin tests, and negative methacholine challenge tests. Cultured NECs or bronchial epithelial HBE1 
cells (59) were analyzed for protein cysteine oxidation and EGFR activation, and the role of  DUOX1 was 
determined using genetic or pharmacologic inhibitor approaches. The importance of  DUOX1 in allergic 
asthma was also evaluated in a mouse model of  HDM-induced allergic inflammation using both male 
and female C57BL/6J wild-type mice (The Jackson Laboratory) and DUOX1-deficient mice, originally 
generated using a retroviral-based gene-trapping method (Lexicon Pharmaceuticals) and backcrossed onto 
a C57BL/6J background (60). In addition, the therapeutic potential of  DUOX1 inhibition during ongo-
ing  asthma exacerbations was assessed by in vivo oropharyngeal administration of  DUOX1-targeted siR-
NA or pharmacological inhibitors in mice 3 days after establishing HDM-induced allergic inflammation. 
HDM-induced allergic inflammation and airway remodeling were assessed by immunohistochemical anal-
yses, RT-PCR, cytokine production by ELISA, analysis of  airways hyperresponsiveness, and Western blot 
analysis of  EGFR activation and protein cysteine oxidation in lung tissues. Animal studies are based on 
2–3 separate experiments with randomized male and female mice and 8–12 mice per experimental group; 
no outliers were excluded from data analyses.
Isolation and culture of  human nasal and bronchoepithelial cells. Primary NECs were collected by gentle 
stroking of  the inferior turbinate surface with a Rhino-Probe curette (Arlington Scientific) and cultured 
as recently described (61) in bronchial epithelial growth medium (Cambrex Bioscience Walkersville Inc.). 
For experiments, NECs were plated on collagen-coated 24-well culture plates (Costar) and cultured in a 
1:1 mixture of  bronchial epithelial cell basic medium and DMEM-H with SingleQuot supplements (Cam-
brex), bovine pituitary extracts (13 mg/ml), bovine serum albumin (1.5 μg/ml), and nystatin (20 units). 
The immortalized bronchial epithelial cell line HBE1 was maintained as described previously (23, 59). 
For in vitro cell studies, cells were grown to confluence in 24-well culture plates (Corning) and incubated 
overnight in full media without EGF to suppress basal EGFR activity, prior to treatment with indicated 
stimuli or inhibitors.
Mouse studies. C57BL6/J or Duox1–/– mice (aged 8–12 weeks) were subjected to brief  isofluorane anesthesia 
for intranasal administration of 50 μg of HDM extract (D. pteronyssinus; Greer Laboratories; 1.27 endotox-
in units/mg) or 50 μl PBS vehicle control, 5 days/week for 3 weeks, and harvested at 3 days after the final 
HDM challenge for the various analyses described below. For intervention studies using Duox1-targeted siRNA 
or NOX inhibitors, C57BL6/J mice were sensitized to HDM by intranasal instillation on days 1 and 8, fol-
lowed by HDM challenge on days 15–19. Three days after the final challenge (day 22), mice were administered 
Duox1-targeted siRNA (two DUOX1 siRNA targets at 35 μg/target sequence/mouse or 70 μg NS siRNA, 
instilled oropharyngeally in mice under brief  isofluorane anesthesia) (21), or the NOX inhibitors DPI (10 μM, 
50 μl) or ML171 (50 μM, 50 μl (36, 37), or appropriate vehicle control, and animals were harvested 3 days later 
(day 25) for various analyses. At harvest, BAL and lung tissues were collected for the various analysis listed 
below. mTECs were isolated from excised mouse tracheas from either wild-type mice or DUOX1-deficient 
mice and cultured as previously described (21) and used at passage 2–3 in in vitro experiments.
siRNA silencing. HBE1 cells were transfected at 60%–70% confluence for transfection with Silencer 
Negative Control #1 siRNA (Invitrogen) or DUOX1-targeted siRNA: (sense) GCUAUGCAGAUGGC-
GUGUAtt, (antisense) UACACGCCAUCUGCAUAGCtg. For in vivo siRNA silencing of  DUOX1, two 
DUOX1 siRNA targets in sterile PBS (35 μg/target sequence/mouse) or NS siRNA (70 μg/mouse) were 
instilled oropharyngeally in mice under brief  isofluorane anesthesia, as detailed previously (21).
Western blotting. Cell lysates or lung homogenates were prepared using Western solubilization buffer (50 
mM HEPES, 250 mM NaCl, 1.5 mM MgCl2, 1% Triton X-100, 10% glycerol, 1 mM EGTA, 1 mM PMSF, 
2 mM Na3VO4, 10 μg/ml aprotinin, 10 μg/ml leupeptin; pH 7.4), and samples containing equal amounts of  
protein (measured using the BCA protein assay kit; Pierce) were separated on 10% SDS-PAGE gels, trans-
ferred to nitrocellulose membranes, and probed with antibodies against EGFR (C74B9; 1:1,000), pEGFR 
Tyr845 (D63B4; 1:500), pEGFR Tyr1068 (D7A5; 1:1,000), and Src (L4A1; 1:1,000) (all from Cell Signal-
ing); p-Src Tyr416 (1:1,000; 07-909; Millipore); or DUOX1 (provided by F. Miot, Free University of  Brus-
sels, Brussels, Belgium) (62). Primarily antibodies were probed with rabbit- or mouse-specific secondary 
antibodies conjugated with HRP (Cell Signaling) and detected by chemiluminescence using SuperSignal 
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West Pico Chemiluminescent Substrate (Pierce). Quantitative EGFR phosphorylation status was assessed 
by densitometry analysis of  pEGFR/EGFR ratios using ImageJ software (NIH).
Analysis of  protein cysteine oxidation. Cells or lung tissues were homogenized in deoxygenated Western 
solubilization buffer containing 1 mM DCP-Bio1 (Kerafast), 200 U/ml catalase (Worthington), and 10 
mM N-ethyl-maleimide (NEM; Sigma-Aldrich); incubated for 1 hour on ice; and centrifuged (5 minutes, 
15,000 g) to remove debris. Excess DCP-Bio1 and NEM were removed by 6 successive washes with 20 mM 
Tris.HCl (pH 7.4) on Amicon Ultra-0.5 Centrifugal Filter Devices (Millipore), and biotin-tagged proteins 
were subsequently purified using NeutrAvidin agarose beads (by overnight incubation with 50 μl of  50:50 
slurry; Pierce), followed by successive washes with 1% SDS, 4 M urea, 1 M NaCl, and 100 mM ammo-
nium bicarbonate (with and without 10 mM DTT) to remove nonspecifically bound proteins (14, 63). 
Avidin-bound proteins were eluted from the beads using 2× reducing sample buffer containing β-mercap-
toethanol (5 minutes; 90°C) and separated by SDS-PAGE for Western blot analysis. Whole cell lysates or 
tissue homogenates were analyzed similarly as input controls.
Histology and immunohistochemistry/immunofluorescence. Left lung lobes were fixed in PFA and paraffin 
embedded, and 5-μm sections were stained with H&E, periodic acid-Schiff  (PAS), or Masson’s trichrome 
using standardized protocols. Fixed sections were also immunostained for α-SMA (Sigma-Aldrich) and 
detected using Vectastain Alkaline Phosphatase Universal (Vector Laboratories) per the manufacturer’s 
instructions. Staining intensity was scored by 3 independent investigators (0, no reactivity; 1, minimal stain-
ing, 2, moderate staining; 3, prominent staining) and positive staining areas were quantified using Meta-
Morph imaging software (Molecular Devices). Lung sections were evaluated for the presence of  DUOX1 
protein using α-DUOX1 (1:200, provided by F. Miot) and Alexa Fluor 555 goat anti-rabbit IgG (Invitro-
gen, 1:500) and counterstained with DAPI. Phosphorylated EGFR was visualized using a phospho-EGFR 
(Tyr1068) rabbit mAb (D7A5; Cell Signaling; 1:125) and visualized by HRP-conjugated secondary anti-
body and the Vectastain Peroxidase ABC Kit (Vector Laboratories), with hematoxylin counterstaining.
Measurement of  airway hyperreactivity. Mice were anesthetized, and tracheas were cannulated and con-
nected to a computer-controlled small animal ventilator (flexiVent; SCIREQ). Mice were paralyzed with 
pancuronium bromide (0.8 μg/kg i.p.), and depth of  anesthesia was monitored continuously with EKG. 
Following stabilization and assessment of  standard lung volume history, mice were exposed to aerosolized 
PBS with incremental doses of  methacholine (12.5, 25, and 50 mg/ml), and respiratory impedance was 
determined using the forced oscillation technique for assessment of  frequency-independent Newtonian 
resistance reflecting the conducting airways (Rn), tissue dampening (G), and tissue stiffness or elastance (H), 
using the constant-phase model of  impedance (64).
ELISAs. Cell culture supernatants or BAL fluids were analyzed for IL-33, IL-5, IL-13, CXCL1/KC, 
and AREG using DuoSet ELISAs from R&D Systems. Serum levels of  HDM-specific IgG1 were deter-
mined by addition of  serial dilutions to ELISA plates precoated with 4 μg/ml HDM and detected with 
biotinylated antibodies against IgG1 or IgE (BD Biosciences) and streptavidin-HRP. MUC5AC ELISA was 
performed using a kit (Mouse Mucin-5 Subtype AC) from MyBioSource according to the manufacturer’s 
instructions.
Preparation and ex vivo stimulation of  lung single-cell suspensions. Lung right lobes were dissociated into 
single-cell suspensions using enzymatic digestion and a GentleMACS Dissociator (Miltenyi Biotec Inc.) 
according to the manufacturer’s recommendations. Total cell counts were performed using a Advia cell 
counter, and single-cell suspensions were cultured at 2 × 106 cells/ml in RPMI 1640 in the absence or 
presence of  IL-33 (10 ng/ml) or HDM (15 μg/ml) for 96 hours, after which supernatants were analyzed for 
IL-5, IL-13, IL-17A, or AREG by ELISA (R&D Systems).
Analysis of  lung ILC2 populations. Lung single-cell suspensions (1 × 106 lung cells) were stained for lin-
eage-negative and ILC2 surface markers using the lineage-negative cocktail (Ly6G [Ly6C], CD45R [B220], 
Ter119, CD3, and CD11b; Biolegend), NK1.1-Alexa700 (Biolegend), CD11c-Alexa700 (Biolegend), 
CD90.2-eflour450 (eBioscience), and Ly6A-PE Cy7 (Biolegend). Dead cells were excluded by UV-Blue 
Live/Dead stain (Life Technologies). Following staining, cells were fixed in DPBS with 1% paraformalde-
hyde and analyzed using a BD LSR II FACS equipped to distinguish as many as 7 fluorophores. Flow data 
were analyzed using FlowJo (Treestar). For flow sorting of  ILC2s, mice were first subjected to 3 successive 
instillations of  IL-33 (1 μg; Biolegend) over 5 days, as described previously (32). Lung single-cell suspen-
sions were performed with the same antibodies described above, and < 2 × 105 ILC2s were sorted using the 
BD FACS Aria high-speed cell sorter and processed for total RNA isolation and RT-qPCR analysis (65).
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RT-PCR. Total cell or tissue RNA was extracted using TRIzol (Invitrogen) and the RNeasy Mini Kit 
(Qiagen) and reverse transcribed using M-MLV reverse transcriptase and Oligo(dT)12–16 primer. qPCR 
was performed using SYBR Green PCR Supermix (Bio-Rad) with predesigned primers (Supplemental 
Table 1) and normalized to GAPDH using the ΔΔCT method.
Statistics. Differences between groups were evaluated by either unpaired 2-tailed t test or 2-way ANOVA 
with Tukey or Bonferroni post-hoc analysis, depending on composition of  data sets, using GraphPad Prism 
version 6.0 (GraphPad). Differences were considered significant when P < 0.05.
Study approval. All studies with human subjects were reviewed and approved by the Institutional Review 
Board of  the University of  Vermont, and all subjects provided written informed consent. All animal proce-
dures were reviewed and approved by the Animal Care and Use Committee of  the University of  Vermont.
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